retatrutide phase 2 results 2024 2025 Today, we shared new data from two 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide Availability and Current Status:

Retatrutide produces substantially greater A1C reductions than metformin monotherapy

It uses liraglutide, a slightly different GLP-1 medication than semaglutide, and requires daily injections rather than weekly

[DOI] [PubMed] [Google Scholar] 107.Saxena AR, Frias JP, Brown LS, et al

Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome

Just as diabetes or hypertension requires ongoing treatment, effective obesity management likely requires sustained intervention

Subsequently, oral formulations and once weekly injections were developed in the 2010s and liraglutide was the first GLP-1 receptor agonist approved for the treatment of obesity in 2014